mrc

Drugs approved for market

Castleman's Disease (Japan) - Actemra®

Crohn's Disease (US) - Tysabri®

Juvenile idiopathic arthritis(Japan) - Actemra®

Multiple sclerosis (EU/US) - Tysabri®

Rheumatoid arthritis (Japan/EU/US) - Actemra®

Drugs currently at clinical trial

Cancer Phase I - ASONEP™

Crohn's Disease Phase II - Actemra®

Crohn's Disease Phase III - MLN0002

Diverse large B-cell lymphoma Phase II - CT-011

Juvenile idiopathic arthritis Phase III - Actemra®

Melanoma Phase I - AS1409

Multiple myeloma Phase II - Actemra®

Relapsed follicular lymphoma Phase II - CT-011

Renal cancer Phase I - AS1409

Ulcerative colitis Phase III - MLN0002

Wet age-related macular degeneration Phase III - iSONEP™

Bone metastases Phase II - MLN1201

Alzheimer's disease Phase I - BAN2401

Multiple myeloma Phase I/IIa - BT062